genedrive plc (AIM: GDR), a point-of-care pharmacogenetic testing company, announced on Wednesday that it has received initial orders for its Genedrive MT-RNR1 products from France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands.

These orders follow the recent confirmation of commercial distribution agreements for the genedrive test addressing antibiotic-induced hearing loss ("AIHL") in several countries. The initial orders will assist genedrive's international distribution partners in promotional and in-country evaluation activities, expanding access to this transformative test globally.

The Genedrive MT-RNR1 ID Kit, the company's flagship product, provides clinicians with rapid, cost-effective and temperature-stable reagent test kits, enabling quick decisions on antibiotic use within 26 minutes.

Headquartered in the UK, genedrive offers a platform that aids clinicians in making informed decisions based on patients' genetic variations. The company's commercial strategy focuses on maximizing in-market sales, geographic and portfolio expansion, and strategic M&A to drive growth. Operating from its facilities in Manchester, genedrive is poised to advance the field of pharmacogenetics for safer and more effective medicine use.